Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

511
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
511
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

830
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
830
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

40
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
40
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

928
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
928
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

495
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
495
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

26
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring hypertension awareness in physicians: a cross-sectional study from Turkey.

Postepy w kardiologii interwencyjnej = Advances in interventional cardiology·2026
Same author

Ablation of Atrioventricular Nodal Reentrant Tachycardia with Focal Cryoablation, Compared with Radiofrequency Ablation: Single-Center Experience.

Arquivos brasileiros de cardiologia·2024
Same author

Management of hypertensive urgencies: a new opportunity for unattended blood pressure measurement.

Journal of human hypertension·2024
Same author

Beta-Blockers and Hypertension: Some Questions and Answers.

High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension·2023
Same author

Combination therapy as a first step of treatment in diabetes: Changing the paradigm in KDIGO guidelines?

European journal of internal medicine·2023
Same author

Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study.

Yonsei medical journal·2023

Related Experiment Video

Updated: Sep 15, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K

New Drugs for Resistant Hypertension: Pending Issue?

Francesco Fici1, Nicolas Roberto Robles2, Istemihan Tengiz3

  • 1Department of Cardiovascular Risk, Salamanca University, Salamanca, Spain;Milano-Bicocca University, Milan, Italy.

Turk Kardiyoloji Dernegi Arsivi : Turk Kardiyoloji Derneginin Yayin Organidir
|July 18, 2025
PubMed
Summary

New antihypertensive drugs are being developed to address the persistent cardiovascular risk in patients with drug-resistant hypertension. This review examines novel drug classes targeting uncontrolled high blood pressure.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

339
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Related Experiment Videos

Last Updated: Sep 15, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.5K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

339
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Discovery

Background:

  • Current antihypertensive drugs reduce cardiovascular risk but do not eliminate it.
  • Elevated cardiovascular risk persists in treated hypertensive patients.
  • There is a need for novel antihypertensive agents for drug-resistant hypertension.

Purpose of the Study:

  • To review emerging antihypertensive drugs for treating drug-resistant hypertension.
  • To highlight novel therapeutic targets and agents in hypertension management.

Main Methods:

  • Literature review of recent studies on new antihypertensive drug classes.
  • Focus on non-steroidal mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and others.

Main Results:

  • Several novel drug classes show promise in targeting resistant hypertension.
  • These include mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and brain renin-angiotensin system blockers.

Conclusions:

  • Novel pharmacological approaches are crucial for managing drug-resistant hypertension.
  • These new agents offer potential to further reduce cardiovascular risk in hypertensive patients.